DeepMed Research

BAUSCH HEALTH AMERICAS, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: 3.1K

Market Cap: -

Website: http://www.bauschhealth.com

Clinical Trials

Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis

Phase 3

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: IDP-118 Lotion
Drug: IDP-118 Vehicle Lotion

First Posted Date: 2015-06-03

Last Posted Date: 2020-08-20

Lead Sponsor: Bausch Health Americas, Inc.

Target Recruit Count: 215

Registration Number: NCT02462122

Locations: 🇺🇸
Valeant Site 13, Detroit, Michigan, United States
🇺🇸
Valeant Site 3, Portland, Oregon, United States
🇺🇸
Valeant Site 15, Houston, Texas, United States

and more 13 locations

The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)

Phase 3

Completed

Conditions: Irritable Bowel Syndrome Characterized by Constipation

Interventions: Drug: Plecanatide
Drug: Placebo

First Posted Date: 2015-03-13

Last Posted Date: 2019-06-14

Lead Sponsor: Bausch Health Americas, Inc.

Target Recruit Count: 1054

Registration Number: NCT02387359

Locations: 🇺🇸
Synergy Research Site, Wauwatosa, Wisconsin, United States
🇺🇸
Synergy Research Site., Nashville, Tennessee, United States

One Year Study of Rifaximin Delayed Release (DR) Tablets in Crohn's Disease

Phase 3

Terminated

Conditions: Crohn's Disease

Interventions: Drug: Rifaximin EIR
Drug: Placebo

First Posted Date: 2014-09-15

Last Posted Date: 2019-09-10

Lead Sponsor: Bausch Health Americas, Inc.

Target Recruit Count: 80

Registration Number: NCT02240121

One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease

Phase 3

Terminated

Conditions: Crohn's Disease

Interventions: Drug: Rifaximin EIR
Drug: Placebo

First Posted Date: 2014-09-15

Last Posted Date: 2019-09-10

Lead Sponsor: Bausch Health Americas, Inc.

Target Recruit Count: 81

Registration Number: NCT02240108

A Bioequivalence Study Comparing a Single 1.5mL Dose of Brodalumab vs. Two Doses (1.0mL + 0.5mL) of Brodalumab

Phase 1

Completed

Conditions: Psoriasis

Interventions: Drug: Brodalumab

First Posted Date: 2014-06-25

Last Posted Date: 2017-06-20

Lead Sponsor: Bausch Health Americas, Inc.

Target Recruit Count: 145

Registration Number: NCT02173392

Locations: 🇺🇸
Research Site, San Antonio, Texas, United States

Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder

Phase 4

Not yet recruiting

Conditions: Major Depressive Disorder

Interventions: Drug: bupropion hydrobromide
Drug: Placebo

First Posted Date: 2014-05-02

Last Posted Date: 2023-02-08

Lead Sponsor: Bausch Health Americas, Inc.

Target Recruit Count: 200

Registration Number: NCT02129751

Locations: 🇺🇸
Valeant, Bridgewater, New Jersey, United States

12-Week Study of Plecanatide for CIC (The National CIC3 Study)

Phase 3

Completed

Conditions: Chronic Idiopathic Constipation

Interventions: Drug: Placebo
Drug: Plecanatide

First Posted Date: 2014-04-24

Last Posted Date: 2019-05-28

Lead Sponsor: Bausch Health Americas, Inc.

Target Recruit Count: 1410

Registration Number: NCT02122471

Locations: 🇺🇸
Synergy Research Site, Richland, Washington, United States

(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: SAN-300 2.0 mg/kg QOW
Drug: Placebo
Drug: SAN-300 0.5 mg/kg QW
Drug: SAN-300 1.0 mg/kg QW
Drug: SAN-300 4.0 mg/kg QOW
Drug: SAN-300 4.0 mg/kg QW

First Posted Date: 2014-01-28

Last Posted Date: 2021-06-21

Lead Sponsor: Bausch Health Americas, Inc.

Target Recruit Count: 41

Registration Number: NCT02047604

Locations: 🇺🇸
Santarus Clinical Investigational Site 1012, Phoenix, Arizona, United States
🇺🇸
Santarus Clinical Investigational Site 1004, El Cajon, California, United States
🇺🇸
Santarus Clinical Investigational Site 1011, San Leandro, California, United States

and more 9 locations

Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis

Phase 2

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: IDP-118 Monad HP Lotion
Drug: IDP-118 Lotion
Drug: IDP-118 Monad Taz Lotion
Drug: IDP-118 Vehicle Lotion

First Posted Date: 2014-01-24

Last Posted Date: 2020-08-20

Lead Sponsor: Bausch Health Americas, Inc.

Target Recruit Count: 212

Registration Number: NCT02045277

Locations: 🇺🇸
Valeant Site 13, Encino, California, United States
🇺🇸
Valeant Site 15, Santa Rosa, California, United States
🇺🇸
Valeant Site 11, San Diego, California, United States

and more 15 locations

Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis

Phase 3

Terminated

Conditions: Psoriatic Arthritis

Interventions: Drug: 210 mg brodalumab
Drug: Placebo
Drug: 140 mg brodalumab

First Posted Date: 2014-01-08

Last Posted Date: 2017-05-19

Lead Sponsor: Bausch Health Americas, Inc.

Target Recruit Count: 478

Registration Number: NCT02029495

Locations: 🇬🇧
Research Site, Manchester, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy